Phase I - Serological Assays for the detection and characterization of influenza viruses
ID: 75D30125R73211_Phase_IType: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFCENTERS FOR DISEASE CONTROL AND PREVENTIONCDC OFFICE OF ACQUISITION SERVICESATLANTA, GA, 30333, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

MEDICAL- LABORATORY TESTING (Q301)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/9b7ce42c9dbe49d7b0d808b6f8712ffd/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is soliciting proposals for a contract focused on the development and execution of serological assays for the detection and characterization of influenza viruses. The primary objectives include performing hemagglutination inhibition assays on human sera for vaccine effectiveness studies and creating a new serology platform that matches the capabilities of existing assays, with an expected testing volume of approximately 6,000 samples annually. This initiative is crucial for enhancing public health responses to influenza through improved detection methodologies and is set within a framework that emphasizes small business participation and adherence to federal acquisition regulations. Interested parties can contact Jennifer Gartzke at jgartzke@cdc.gov or by phone at 404-498-0020 for further details, with the contract performance period commencing on April 28, 2025, and extending through optional periods thereafter.

    Point(s) of Contact
    Jennifer Gartzke
    (404) 498-0020
    jgartzke@cdc.gov
    Files
    Title
    Posted
    A19_75D301-25-R-73211.pdf
    The document outlines a solicitation for a contract with the Centers for Disease Control and Prevention (CDC) aimed at providing services for serological assays to detect and characterize influenza viruses. The contract includes a base period from April 28, 2025, to April 27, 2026, with four optional extension periods. The primary objectives are to perform hemagglutination inhibition assays on human samples for vaccine effectiveness studies and to develop improved serology assays using high-throughput technology. Key deliverables involve testing approximately 6,000 samples per year, with optional surge support for increased testing as needed. The contractor will be responsible for providing necessary services, including sample testing, training, and developing standard operating procedures. The government will provide controls, protocols, and samples required for validations. The performance metrics are established to ensure timely and accurate reporting, with strict adherence to safety and operational standards. This competitive procurement emphasizes small business participation and is aligned with federal acquisition regulations, emphasizing a performance-based approach to contracting. Overall, this solicitation represents an effort to enhance public health capabilities through improved influenza virus detection methodologies.
    Similar Opportunities
    Serological Assays for the detection and characterization of influenza viruses
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking contractors for the provision of serological assays aimed at detecting and characterizing influenza viruses. This contract encompasses a 12-month base period with four additional 12-month option periods, focusing on testing immunological responses from human samples collected during vaccine effectiveness studies, randomized controlled trials, and outbreak investigations using Hemagglutination Inhibition (HAI) assays. The services are critical for understanding vaccine efficacy and managing influenza outbreaks, with the government supplying necessary standard operating procedures, proficiency panels, and controls to ensure proper assay performance. Interested parties should contact Jennifer Gartzke at jgartzke@cdc.gov or 404-498-0020 for further details, as this opportunity is set aside for small businesses under the SBA guidelines.
    Diagnostic Test Development and Production for Emergency Response
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking proposals for the development and production of diagnostic tests aimed at enhancing emergency response capabilities for public health threats. The procurement involves multiple tasks, including the rapid development and validation of Nucleic Acid Amplification Tests for selected pathogens, regulatory submissions for Emergency Use Authorization (EUA), and the manufacturing of tests to meet outbreak demands. This initiative is critical for bolstering the national laboratory system's readiness and efficiency in addressing public health emergencies. Interested vendors must submit their proposals by December 13, 2024, with a maximum contract value of $148 million and a minimum order of $10,000. For further inquiries, vendors can contact Shayna Connery at xvj9@cdc.gov or Austin Pagliaccetti at zsm6@cdc.gov.
    Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking proposals for the "Rapid Pandemic Influenza and Emergency Infectious Disease Vaccine Development and Response Capability" through a Special Notice. The objective of this procurement is to establish a long-term partnership focused on developing a flexible and rapid response capability for vaccine development against pandemic influenza and other priority pathogens, initially emphasizing influenza mRNA vaccine development. This initiative is critical for enhancing the nation's preparedness and response to emerging infectious diseases, ensuring readiness to pivot quickly in the face of public health threats. Interested parties can access the full Request for Project Proposals and additional consortium information at www.rrpv.org, and inquiries can be directed to Rebecca Harmon at rebecca.harmon@ati.org.
    Increasing Community Access to Testing and Treatment (ICATT) Pharmacy Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Centers for Disease Control and Prevention (CDC), is seeking partnerships with private contractors for the Increasing Community Access to Testing, Treatment, and Prevention (ICATT) Pharmacy Services program, which will run from June 1, 2025, to May 31, 2030. The procurement aims to provide comprehensive healthcare services, including nationwide testing, medical assessments, therapeutics, vaccinations, and emergency response capabilities, particularly targeting under-resourced communities. This initiative builds on the successful efforts during the COVID-19 pandemic and emphasizes the importance of public-private partnerships in enhancing public health infrastructure and accessibility. Interested contractors should submit their detailed responses to the Request for Information by October 22, 2024, with inquiries due by November 4, 2024; for further information, contact Dawn Redman at dredman@cdc.gov or Jorge Morales at xvx7@cdc.gov.
    CDC DFWED NARST Sensititre Supplies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking to award a sole source contract for antimicrobial resistance testing supplies, specifically Sensititre™ broth microdilution testing products, from ThermoFisher Scientific. This procurement is essential for the National Antimicrobial Resistance Monitoring System (NARMS), which has utilized these proprietary materials since 1996 to ensure a standardized approach to monitoring enteric bacteria resistance. The unique nature of these supplies necessitates this sole source approach, as alternatives would require significant investments in new equipment and validation processes, potentially disrupting critical surveillance efforts. Interested parties may respond within 15 days to express their interest, with proposals directed to contract specialist Ashley Williams at dal3@cdc.gov.
    Notice of Intent to Sole Source - Biosearch Technologies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) intends to negotiate a sole source contract with Biosearch Technologies, Inc. for the production of PCR kits essential for the Laboratory Response Network (LRN). The procurement aims to secure proprietary reagents necessary for detecting biothreat and emerging infectious disease agents, which are critical for the preparedness and response capabilities of various federal and state agencies. These kits, which must adhere to FDA quality standards, are vital for high-security laboratories in identifying potential bioterrorism agents and ensuring public health safety. Interested parties may submit capability statements or proposals to Matthew Nelson at mnelson2@cdc.gov by December 3, 2024, at 3:30 PM EST for consideration.
    Notice of the Intent to Sole Source to Roche Diagnostics for the purchase of the Cobas 5800 Classic Service Package.
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price purchase order to Roche Diagnostics for the Cobas 5800 Classic Service Package. This procurement is necessary due to the exclusive licensing agreements and proprietary data restrictions associated with the Cobas 5800 equipment, which limits service provision to Roche Diagnostics alone. The services are critical for maintaining the functionality of laboratory instruments essential for public health operations. Interested parties may express their interest and capability to respond to this requirement by emailing the contract specialist, Robert Iaropoli, at zlb5@cdc.gov, by 6:30 AM EDT on December 2, 2024. Responses received within this timeframe will be considered by the government, although this notice does not constitute a request for competitive quotations.
    SERVICE AGREEMENT FOR A FACSYMPHONY S6 SORTER
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is seeking quotes for a service agreement for a FACSymphony S6 sorter and associated lasers. The contract aims to ensure the maintenance and optimal operation of flow cytometers and related equipment critical for research on immune responses in HIV- and SIV-infected samples. This service agreement is essential for the uninterrupted functionality of the equipment used in the Vaccine Research Center's Flow Cytometry Core, with a performance period from February 1, 2025, to January 31, 2026. Interested vendors must submit their quotes by November 25, 2024, at 12:00 PM EST, and can contact Mildred Moss at mildred.moss@nih.gov or Tonia Alexander at talexander@niaid.nih.gov for further information.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 NIAID DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing medical countermeasures against infectious diseases. This opportunity encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant pathogens, and the creation of direct acting antivirals targeting viruses with pandemic potential. The initiative is critical for enhancing public health responses to emerging infectious threats and includes funding estimates of up to $8.5 million for Research Area 001 and $20 million for Research Area 002, with proposals due to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) platform, starting around November 22, 2024. For further inquiries, interested parties may contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov.
    SERVICE AGREEMENT FOR A FACSYMPHONY S6 SORTER
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking a qualified contractor to provide a service agreement for a FACSymphony S6 sorter and associated lasers, essential for maintaining optimal operation of flow cytometry equipment used in critical research. The contract includes provisions for preventive maintenance inspections, unlimited service visits, and priority onsite scheduling to minimize downtime, ensuring that the equipment remains functional for ongoing research into immune responses in HIV- and SIV-infected samples. Interested vendors must submit their quotes via the NIAID electronic Simplified Acquisition Submission System (eSASS) by November 25, 2024, with the contract period set from February 1, 2025, to January 31, 2026. For further inquiries, vendors can contact Mildred Moss at mildred.moss@nih.gov or Tonia Alexander at talexander@niaid.nih.gov.